Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.
about
Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patientsSelf-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansionHuman-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and TMethylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasmsDifferential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cellsSex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders.Two clinical phenotypes in polycythemia vera.Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patientsGenomic alterations in abnormal neutrophils isolated from adult patients with systemic lupus erythematosusDisruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypesAbdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report.Intrinsic resistance to JAK2 inhibition in myelofibrosis.The polycythemia vera stem cell.Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasmsMicroRNA deregulation in polycythemia vera and essential thrombocythemia patients.MicroRNAs in myeloproliferative neoplasms.Therapeutic potential of JAK2 inhibitors.Experimental therapeutics for patients with myeloproliferative neoplasias.Prognosis of Primary Myelofibrosis in the Genomic EraJAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.JAK2 V617F allele burden quantified by real time quantitative polymerase chain reaction and competitive polymerase chain reaction in patients with chronic myeloproliferative neoplasia.Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia.
P2860
Q26799388-FF13B90D-0355-4D5A-9F16-92EC27E036F6Q27317353-65D4F926-C3F3-4728-AB41-10139F117507Q33560423-A68C2075-A9B3-4F0F-A8C3-4F22736F5FCFQ33572605-054967E2-1AC3-4FE8-AB1B-4088CEDDECDBQ33880512-08136322-0D68-4D10-A2BB-E5C6AD856F64Q33894805-864389DF-688D-4DE2-A45E-CEA8071AB504Q33952753-91D1A5A2-089D-4124-B2D6-9FBBC87069A4Q34415448-16D5C52B-0871-424E-8700-023C47DC746DQ34419687-5597DE83-3655-4CE6-BA5E-C90395EA638FQ34672353-05CDE703-9378-4F92-BBEB-C3D19E1D6BF6Q35265880-322B67DE-E3F7-4C69-8B0C-B0269B2474CCQ35950662-0E7FC89F-9767-484E-B93B-B09709A5F650Q36745581-A5F559AB-AA26-4313-8C48-38942EFD971AQ36852469-0B2C4AAF-7550-4C99-A051-2064BE026FFFQ37262428-CD80AFA3-A603-4014-A127-431BB23995E8Q37408774-A5538E9C-B512-4382-A959-71D13ED74737Q37529812-F174B89F-455E-4113-9C9A-AAFF5B6AD34FQ37653313-17FCEB88-0500-4D3D-AD29-6F4E97CE299CQ37797983-438C5149-652C-4B8A-B9CA-34E3B666E3E2Q38926804-43C4E93C-F026-413E-B759-0A944616B24CQ41545614-F0E6164E-6C78-423E-90DD-49E8202DAA54Q48226545-3643F39B-40E0-4B18-A73D-ABC304B1728EQ49834761-E378AF8C-1933-4A0E-9D00-A59A49C81C89Q51053290-937F0082-1427-474C-BC41-E8C848E4F81AQ54333616-E37E6C79-1729-4F08-8BD5-B750D140D763Q54346714-9D84A26D-7842-448C-9BD4-9FF16D97C3E8Q54772815-6A0FDABD-4D57-4F72-99BA-D8E7F6FFF5AE
P2860
Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phenotypic variability within ...... and neutrophil allele burdens.
@en
Phenotypic variability within ...... and neutrophil allele burdens.
@nl
type
label
Phenotypic variability within ...... and neutrophil allele burdens.
@en
Phenotypic variability within ...... and neutrophil allele burdens.
@nl
prefLabel
Phenotypic variability within ...... and neutrophil allele burdens.
@en
Phenotypic variability within ...... and neutrophil allele burdens.
@nl
P2093
P2860
P1476
Phenotypic variability within ...... and neutrophil allele burdens.
@en
P2093
Alison R Moliterno
Donna M Williams
Jerry L Spivak
Mary Ann Isaacs
Ophelia Rogers
P2860
P304
P356
10.1016/J.EXPHEM.2008.05.006
P577
2008-08-23T00:00:00Z